RXRB

Summary

RXRB (retinoid X receptor beta, HGNC:10478) is a protein-coding gene on chromosome 6p21.32, encoding Retinoic acid receptor RXR-beta (P28702). Receptor for retinoic acid.

This gene encodes a member of the retinoid X receptor (RXR) family of nuclear receptors which are involved in mediating the effects of retinoic acid (RA). The encoded protein forms homodimers with the retinoic acid, thyroid hormone, and vitamin D receptors, increasing both DNA binding and transcriptional function on their respective response elements. This gene lies within the major histocompatibility complex (MHC) class II region on chromosome 6. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 6257 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 69 total
• Druggable target: yes — 6 molecules with ChEMBL bioactivity
• Transcription factor: yes — 19 downstream targets (CollecTRI)
• MANE Select transcript: NM_021976

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10478
Approved symbol	RXRB
Name	retinoid X receptor beta
Location	6p21.32
Locus type	gene with protein product
Status	Approved
Aliases	NR2B2, H-2RIIBP, RCoR-1, RXRbeta, RXR-beta
Ensembl gene	ENSG00000204231
Ensembl biotype	protein_coding
OMIM	180246
Entrez	6257

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 10 protein_coding, 2 retained_intron, 1 nonsense_mediated_decay

ENST00000374680, ENST00000374685, ENST00000481441, ENST00000483281, ENST00000483821, ENST00000865272, ENST00000865273, ENST00000865274, ENST00000865275, ENST00000865276, ENST00000865277, ENST00000865278, ENST00000912952

RefSeq mRNA: 3 — MANE Select: NM_021976 NM_001270401, NM_001291989, NM_021976

CCDS: CCDS4768, CCDS59007

Canonical transcript exons

ENST00000374680 — 10 exons

Exon	Start	End
ENSE00001726956	33199169	33199416
ENSE00001854541	33200242	33200665
ENSE00001946150	33193588	33194829
ENSE00003458331	33195570	33195702
ENSE00003490395	33194945	33195050
ENSE00003513613	33195363	33195454
ENSE00003568955	33197762	33197941
ENSE00003580725	33196434	33196606
ENSE00003629815	33198308	33198464
ENSE00003644074	33195907	33196036

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 96.26.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 28.4122 / max 143.4359, expressed in 1813 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
73105	19.6379	1798
73104	8.5437	1751
73103	0.1937	109
73102	0.0369	17

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of thyroid gland	UBERON:0001119	96.26	gold quality
granulocyte	CL:0000094	96.06	gold quality
mucosa of stomach	UBERON:0001199	96.05	gold quality
left lobe of thyroid gland	UBERON:0001120	96.03	gold quality
right coronary artery	UBERON:0001625	95.92	gold quality
right uterine tube	UBERON:0001302	95.75	gold quality
body of uterus	UBERON:0009853	95.72	gold quality
thyroid gland	UBERON:0002046	95.71	gold quality
right ovary	UBERON:0002118	95.59	gold quality
pituitary gland	UBERON:0000007	95.58	gold quality
endocervix	UBERON:0000458	95.57	gold quality
right hemisphere of cerebellum	UBERON:0014890	95.50	gold quality
apex of heart	UBERON:0002098	95.35	gold quality
tibial nerve	UBERON:0001323	95.34	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.30	gold quality
spleen	UBERON:0002106	95.28	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	95.25	gold quality
adenohypophysis	UBERON:0002196	95.20	gold quality
left ovary	UBERON:0002119	95.18	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.13	gold quality
lower esophagus	UBERON:0013473	95.12	gold quality
left uterine tube	UBERON:0001303	95.07	gold quality
cerebellum	UBERON:0002037	95.00	gold quality
cerebellar cortex	UBERON:0002129	95.00	gold quality
cerebellar hemisphere	UBERON:0002245	95.00	gold quality
tibial artery	UBERON:0007610	94.96	gold quality
popliteal artery	UBERON:0002250	94.94	gold quality
fundus of stomach	UBERON:0001160	94.93	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.88	gold quality
ascending aorta	UBERON:0001496	94.86	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.35

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

19 targets.

Target	Regulation
ABCG1
ALDH1A1	Activation
CD74
CRYAB
CTNNB1
GH1
GPRC5A
ICAM1	Unknown
IFNG	Activation
LRP1
PCP2
PKD1	Activation
PTH	Repression
RARB	Activation
RBP1	Repression
RBP2	Unknown
SUPT7L
TRH
TSHB

JASPAR motifs

Motif	Name	Family
MA0855.1	RXRB	RXR-related receptors (NR2)
MA1555.1	RXRB	RXR-related receptors (NR2)

JASPAR matrix evidence (PMIDs): PMID:15019979, PMID:14559106

Upstream regulators (CollecTRI, top): THRA

miRNA regulators (miRDB)

57 targeting RXRB, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-3682-5P	99.93	67.97	1163
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-6132	99.60	65.83	1554
HSA-MIR-6836-5P	99.60	65.62	1538
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-4753-5P	99.54	68.51	1356
HSA-MIR-6828-5P	99.31	69.21	1433
HSA-MIR-4685-5P	99.25	65.99	1563
HSA-MIR-6837-5P	99.25	65.47	1632
HSA-MIR-1253	99.12	67.08	1688
HSA-MIR-7854-3P	99.08	66.26	1117
HSA-MIR-622	98.99	66.48	1050
HSA-MIR-6770-5P	98.97	66.76	1853
HSA-MIR-3922-5P	98.77	66.53	1059

Literature-anchored findings (GeneRIF, showing 13)

• The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer (PMID:11839661)
• polymorphism is unrelated to schizophrenia or alcoholism. (PMID:11840500)
• Family studies revealed significant linkage disequilibrium between the RXRB alleles and a number of HLA-DPB1 alleles. (PMID:12175732)
• Diminished RXRbeta expression might be related to prostate cancer progression. Because responsiveness to retinoic acid treatments depends on expression of different receptors, it is important to study their expression before therapy. (PMID:12514092)
• partial dissociation of TR/retinoid X receptor heterodimer complex from the TRE is involved in the suppression of transcription induced by polychlorinated biphenyls (PMID:14985366)
• The retinoid X receptor, beta is expressed widely and can be found in almost every tissue. (PMID:15608692)
• In the RXRB polymorphism, no genotype TT is observed in patients with psoriasis guttata with a positive personal history of repeated tonsillitis (p(corr) = 0.001). (PMID:17341859)
• In healthy elderly men reduction of RXRbeta expression in peripheral blood mononuclear cells might be a common feature of physiological senescence. (PMID:17916375)
• PPARgamma/retinoid X receptor complex released from activated platelets in microparticles was internalized by a monocytic cell line. (PMID:18217139)
• A fatty acid-binding protein 7/RXRbeta pathway enhances survival and proliferation in triple-negative breast cancer. (PMID:22322885)
• RXR interaction is necessary for NPM-RAR-mediated myeloid maturation arrest. (PMID:24183235)
• Data show that pregnane X receptor/retinoid X receptor PXR/RXR-[alpha], RXR-[beta], or RXR-[gamma] expression was noted in 9 (16.4%), 9 (16.4%), and 10 (18.2%) pancreatic adenocarcinoma cases, respectively. (PMID:26355550)
• Genetic variant of RXR involved in the vitamin D metabolic pathway was linked to HCV infection outcomes among a high-risk Chinese population. (PMID:33246082)

Cross-species orthologs

31 orthologs

Organism	Symbol	Gene ID
danio_rerio	rxrbb	ENSDARG00000002006
danio_rerio	rxrba	ENSDARG00000078954
mus_musculus	Rxrb	ENSMUSG00000039656
rattus_norvegicus	Rxrb	ENSRNOG00000000464
drosophila_melanogaster	usp	FBGN0003964
drosophila_melanogaster	Hr78	FBGN0015239
drosophila_melanogaster	Hr83	FBGN0037436
caenorhabditis_elegans		WBGENE00003626
caenorhabditis_elegans		WBGENE00003650
caenorhabditis_elegans	nhr-69	WBGENE00003659
caenorhabditis_elegans		WBGENE00003683
caenorhabditis_elegans		WBGENE00003706
caenorhabditis_elegans		WBGENE00003719
caenorhabditis_elegans		WBGENE00003726
caenorhabditis_elegans		WBGENE00007547
caenorhabditis_elegans		WBGENE00008221
caenorhabditis_elegans		WBGENE00011097
caenorhabditis_elegans		WBGENE00011098
caenorhabditis_elegans		WBGENE00011099
caenorhabditis_elegans		WBGENE00011100
caenorhabditis_elegans		WBGENE00015395
caenorhabditis_elegans		WBGENE00015396
caenorhabditis_elegans		WBGENE00015397
caenorhabditis_elegans		WBGENE00015705
caenorhabditis_elegans		WBGENE00016975
caenorhabditis_elegans		WBGENE00017198
caenorhabditis_elegans		WBGENE00017787
caenorhabditis_elegans		WBGENE00020748
caenorhabditis_elegans		WBGENE00021848
caenorhabditis_elegans		WBGENE00022423
caenorhabditis_elegans		WBGENE00044354

Paralogs (11): HNF4A (ENSG00000101076), NR2E1 (ENSG00000112333), NR2C1 (ENSG00000120798), RXRG (ENSG00000143171), NR2F6 (ENSG00000160113), HNF4G (ENSG00000164749), NR2F1 (ENSG00000175745), NR2C2 (ENSG00000177463), NR2F2 (ENSG00000185551), RXRA (ENSG00000186350), NR2E3 (ENSG00000278570)

Protein

Protein identifiers

Retinoic acid receptor RXR-beta — P28702 (reviewed: P28702)

Alternative names: Nuclear receptor subfamily 2 group B member 2, Retinoid X receptor beta

All UniProt accessions (5): A0A0S2Z4M5, A0A0S2Z570, E9PK75, P28702, Q5STP9

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE).

Subunit / interactions. Homodimer (in vitro). Heterodimer with other retinoic acid receptor family members. Binds DNA preferentially as a RAR/RXR heterodimer. Interacts with NR1H3. Interacts with AKAP13.

Subcellular location. Nucleus. Cytoplasm.

Tissue specificity. Expressed in aortic endothelial cells (at protein level). Expressed in monocytes. Expressed in a variety of tumor cell lines.

Domain organisation. Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain.

Induction. Down-regulated by aging.

Similarity. Belongs to the nuclear hormone receptor family. NR2 subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
P28702-1	1	yes
P28702-3	2

RefSeq proteins (3): NP_001257330, NP_001278918, NP_068811* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000003	Retinoid-X_rcpt/HNF4	Family
IPR000536	Nucl_hrmn_rcpt_lig-bd	Domain
IPR001628	Znf_hrmn_rcpt	Domain
IPR001723	Nuclear_hrmn_rcpt	Family
IPR013088	Znf_NHR/GATA	Homologous_superfamily
IPR035500	NHR-like_dom_sf	Homologous_superfamily
IPR050274	Nuclear_hormone_rcpt_NR2	Family

Pfam: PF00104, PF00105

UniProt features (37 total): helix 12, compositionally biased region 8, region of interest 6, strand 2, zinc finger region 2, chain 1, domain 1, modified residue 1, DNA-binding region 1, splice variant 1, sequence conflict 1, turn 1

Structure

Experimental structures (PDB)

7 structures.

PDB	Method	Resolution (Å)
7A78	X-RAY DIFFRACTION	1.72
5KYA	X-RAY DIFFRACTION	2.6
5HJP	X-RAY DIFFRACTION	2.6
5I4V	X-RAY DIFFRACTION	2.61
1H9U	X-RAY DIFFRACTION	2.7
5KYJ	X-RAY DIFFRACTION	2.8
1UHL	X-RAY DIFFRACTION	2.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P28702-F1	72.81	0.49

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 25

Function

Pathways and Gene Ontology

Reactome pathways

18 pathways

ID	Pathway
R-HSA-1989781	PPARA activates gene expression
R-HSA-383280	Nuclear Receptor transcription pathway
R-HSA-5362517	Signaling by Retinoic Acid
R-HSA-9029558	NR1H2 & NR1H3 regulate gene expression linked to lipogenesis
R-HSA-9029569	NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
R-HSA-9031525	NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake
R-HSA-9031528	NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose
R-HSA-9623433	NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis
R-HSA-9632974	NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis
R-HSA-1430728	Metabolism
R-HSA-162582	Signal Transduction
R-HSA-212436	Generic Transcription Pathway
R-HSA-400206	Regulation of lipid metabolism by PPARalpha
R-HSA-556833	Metabolism of lipids
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-9006931	Signaling by Nuclear Receptors
R-HSA-9024446	NR1H2 and NR1H3-mediated signaling

MSigDB gene sets: 258 (showing top): GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_MUSCLE_TISSUE_DEVELOPMENT, KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY, MACLACHLAN_BRCA1_TARGETS_DN, GOBP_CELLULAR_RESPONSE_TO_LIPID, MORF_SNRP70, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GOBP_GROWTH, GOBP_STRIATED_MUSCLE_CELL_DIFFERENTIATION, GOBP_VENTRICULAR_CARDIAC_MUSCLE_CELL_DIFFERENTIATION, GOBP_MUSCLE_CELL_PROLIFERATION, BROWNE_HCMV_INFECTION_12HR_UP, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, USF_C

GO Biological Process (16): in utero embryonic development (GO:0001701), maternal placenta development (GO:0001893), nervous system development (GO:0007399), hormone-mediated signaling pathway (GO:0009755), cell differentiation (GO:0030154), positive regulation of bone mineralization (GO:0030501), mRNA transcription by RNA polymerase II (GO:0042789), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), retinoic acid receptor signaling pathway (GO:0048384), ventricular cardiac muscle cell differentiation (GO:0055012), cardiac muscle cell proliferation (GO:0060038), positive regulation of vitamin D receptor signaling pathway (GO:0070564), cellular response to retinoic acid (GO:0071300), regulation of DNA-templated transcription (GO:0006355), nuclear receptor-mediated steroid hormone signaling pathway (GO:0030518)

GO Molecular Function (15): RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), nuclear steroid receptor activity (GO:0003707), nuclear receptor activity (GO:0004879), zinc ion binding (GO:0008270), chromatin DNA binding (GO:0031490), retinoic acid-responsive element binding (GO:0044323), sequence-specific double-stranded DNA binding (GO:1990837), transcription cis-regulatory region binding (GO:0000976), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700), protein binding (GO:0005515), sequence-specific DNA binding (GO:0043565), metal ion binding (GO:0046872)

GO Cellular Component (7): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), cytosol (GO:0005829), RNA polymerase II transcription regulator complex (GO:0090575), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-9 pathways:

Category	Pathways
NR1H2 and NR1H3-mediated signaling	6
Signaling by Nuclear Receptors	2
Regulation of lipid metabolism by PPARalpha	1
Generic Transcription Pathway	1
RNA Polymerase II Transcription	1
Metabolism of lipids	1
Metabolism	1
Gene expression (Transcription)	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
transcription by RNA polymerase II	2
DNA-templated transcription	2
regulation of DNA-templated transcription	2
regulation of transcription by RNA polymerase II	2
nuclear receptor-mediated signaling pathway	2
transcription cis-regulatory region binding	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
DNA-binding transcription factor activity, RNA polymerase II-specific	2
DNA binding	2
nuclear lumen	2
chordate embryonic development	1
placenta development	1
developmental process involved in reproduction	1
anatomical structure development	1
maternal process involved in female pregnancy	1
system development	1
signal transduction	1
cellular response to hormone stimulus	1
cellular developmental process	1
bone mineralization	1
regulation of bone mineralization	1
positive regulation of ossification	1
positive regulation of biomineral tissue development	1
mRNA transcription	1
positive regulation of RNA biosynthetic process	1
positive regulation of DNA-templated transcription	1
hormone-mediated signaling pathway	1
cardiac muscle cell differentiation	1
striated muscle cell proliferation	1
cardiac muscle tissue growth	1
vitamin D receptor signaling pathway	1
regulation of vitamin D receptor signaling pathway	1
positive regulation of intracellular signal transduction	1
response to retinoic acid	1
cellular response to lipid	1
cellular response to oxygen-containing compound	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
steroid hormone receptor signaling pathway	1

Protein interactions and networks

STRING

1094 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RXRB	COL11A2	P13942	804
RXRB	SLC39A7	Q92504	797
RXRB	HSD17B8	Q92506	795
RXRB	RGL2	O15211	770
RXRB	RARS1	P54136	761
RXRB	RARA	P10276	757
RXRB	RARB	P10826	755
RXRB	KIFC1	Q9BW19	745
RXRB	RPS18	P25232	735
RXRB	CNOT7	Q9UIV1	671
RXRB	RING1	Q06587	665
RXRB	PFDN6	O15212	665
RXRB	PPARD	Q03181	595
RXRB	NCOR1	O75376	584
RXRB	PPARA	Q07869	545

IntAct

122 interactions, top by confidence:

A	B	Type	Score
RXRB	RARA	psi-mi:“MI:0915”(physical association)	0.950
RARA	RXRB	psi-mi:“MI:0915”(physical association)	0.950
RARB	RXRB	psi-mi:“MI:0915”(physical association)	0.810
RXRB	RARB	psi-mi:“MI:0915”(physical association)	0.810
RARA	NCOR1	psi-mi:“MI:0914”(association)	0.800
RXRB	NR1H4	psi-mi:“MI:0915”(physical association)	0.790
NR1H4	RXRB	psi-mi:“MI:0915”(physical association)	0.790
RARG	RXRB	psi-mi:“MI:0915”(physical association)	0.740
RXRB	NR1H3	psi-mi:“MI:0915”(physical association)	0.720

BioGRID (97): RXRB (Two-hybrid), NR1H3 (Two-hybrid), RXRB (Affinity Capture-Western), RXRB (Affinity Capture-Western), RXRB (Affinity Capture-Western), RXRB (Affinity Capture-MS), RXRB (Two-hybrid), SPOP (Two-hybrid), NCOA1 (Two-hybrid), ADRBK1 (Affinity Capture-MS), CCNK (Affinity Capture-MS), CDC42BPB (Affinity Capture-MS), C2CD5 (Affinity Capture-MS), POLR3F (Affinity Capture-MS), AFF4 (Affinity Capture-MS)

ESM2 similar proteins: A0A0G2JUG7, A1YER5, A1YFY1, A2T6X5, B2DD29, C0HBT3, O08629, O15156, O15169, O35730, O60307, O95343, P0C0T2, P28702, P28704, P29353, P50241, P98083, Q06587, Q0IHB0, Q13263, Q2V2M9, Q2YDU3, Q3U1V8, Q3U2S4, Q4KMP7, Q5DU25, Q5JU85, Q5PRF9, Q5R7W7, Q5RBI7, Q5RJI5, Q5TJF3, Q5TJF7, Q62233, Q62318, Q66J69, Q68DC2, Q6MGB6, Q6ZRS2

Diamond homologs: A2T928, A2T929, A4IIG7, O35507, O42295, O42450, O57606, O77245, O97716, P03373, P04625, P10276, P10826, P10827, P10828, P11416, P12813, P13631, P15204, P17671, P18113, P18115, P18117, P18119, P18514, P18515, P18516, P18911, P19793, P22448, P22605, P22736, P22829, P28699, P28700, P28701, P28702, P28704, P28705, P37242

SIGNOR signaling

24 interactions.

A	Effect	B	Mechanism
RXRB	up-regulates	PPARA	binding
RXRB	up-regulates	PPARD	binding
RXRB	up-regulates	PPARG	binding
RXRB	up-regulates	NR1H2	binding
RARB	up-regulates	RXRB	binding
RARG	up-regulates	RXRB	binding
RXRB	up-regulates	RARA	binding
RXRB	up-regulates	RARB	binding
RXRB	“up-regulates quantity by expression”	RARB	“transcriptional regulation”
RXRB	up-regulates	RARG	binding
“all-trans-retinoic acid”	“up-regulates activity”	RXRB	“chemical activation”
bexarotene	“up-regulates activity”	RXRB	“chemical activation”
“9-cis-retinoic acid”	“up-regulates activity”	RXRB	“chemical activation”
RXRB	“up-regulates activity”	THR	binding
RXRB	up-regulates	RAR	binding
RXRB	up-regulates	THR	binding
RXRB	up-regulates	NR4A2	binding
RXRB	up-regulates	NR2F1	binding
RXRB	up-regulates	NR2F2	binding
RXRB	up-regulates	THRA	binding
RXRB	up-regulates	THRB	binding
RXRB	up-regulates	NRIP1	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 50 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SUMOylation of intracellular receptors	9	75.6×	2e-13
Nuclear Receptor transcription pathway	12	60.1×	1e-16
PPARA activates gene expression	6	14.2×	2e-04
Activation of anterior HOX genes in hindbrain development during early embryogenesis	5	11.4×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
intracellular receptor signaling pathway	5	103.3×	3e-07
retinoic acid receptor signaling pathway	7	94.5×	3e-10
mRNA transcription by RNA polymerase II	6	41.3×	1e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

69 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	48
Likely benign	10
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

1289 predictions. Top by Δscore:

Variant	Effect	Δscore
6:33194827:AACC:A	acceptor_loss	1.0000
6:33194829:CCT:C	acceptor_loss	1.0000
6:33194940:CTCAC:C	donor_loss	1.0000
6:33194941:TCA:T	donor_loss	1.0000
6:33194942:CACCG:C	donor_loss	1.0000
6:33194943:A:T	donor_loss	1.0000
6:33194944:C:CG	donor_loss	1.0000
6:33194944:CCGT:C	donor_gain	1.0000
6:33194947:T:TA	donor_gain	1.0000
6:33194948:C:A	donor_gain	1.0000
6:33194964:A:AC	donor_gain	1.0000
6:33194965:C:CC	donor_gain	1.0000
6:33194965:CTT:C	donor_gain	1.0000
6:33194967:T:TA	donor_gain	1.0000
6:33195049:ATCTG:A	acceptor_loss	1.0000
6:33195050:TCTGG:T	acceptor_loss	1.0000
6:33195051:C:CC	acceptor_gain	1.0000
6:33195051:CTGGG:C	acceptor_loss	1.0000
6:33195056:A:AC	acceptor_gain	1.0000
6:33195060:C:CT	acceptor_gain	1.0000
6:33195061:A:T	acceptor_gain	1.0000
6:33195568:A:AC	donor_gain	1.0000
6:33195569:C:CC	donor_gain	1.0000
6:33195588:A:AC	donor_gain	1.0000
6:33195589:C:CC	donor_gain	1.0000
6:33196032:TTTGG:T	acceptor_gain	1.0000
6:33196470:AACGC:A	donor_gain	1.0000
6:33196474:C:CA	donor_gain	1.0000
6:33197756:CCTTA:C	donor_loss	1.0000
6:33197757:CTTA:C	donor_loss	1.0000

AlphaMissense

3418 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:33194707:A:G	L526P	1.000
6:33194707:A:T	L526H	1.000
6:33194719:A:C	L522R	1.000
6:33194719:A:G	L522P	1.000
6:33194719:A:T	L522H	1.000
6:33194721:G:C	F521L	1.000
6:33194721:G:T	F521L	1.000
6:33194722:A:C	F521C	1.000
6:33194722:A:G	F521S	1.000
6:33194723:A:G	F521L	1.000
6:33194728:T:A	D519V	1.000
6:33194731:A:T	I518N	1.000
6:33194743:C:A	G514V	1.000
6:33194743:C:T	G514D	1.000
6:33194746:A:T	I513N	1.000
6:33194749:A:G	L512P	1.000
6:33194749:A:T	L512H	1.000
6:33194754:G:C	F510L	1.000
6:33194754:G:T	F510L	1.000
6:33194755:A:G	F510S	1.000
6:33194756:A:G	F510L	1.000
6:33194757:G:C	F509L	1.000
6:33194757:G:T	F509L	1.000
6:33194759:A:G	F509L	1.000
6:33194760:A:C	F508L	1.000
6:33194760:A:T	F508L	1.000
6:33194761:A:C	F508C	1.000
6:33194761:A:G	F508S	1.000
6:33194762:A:G	F508L	1.000
6:33194762:A:T	F508I	1.000

dbSNP variants (sampled 300 via entrez): RS1000491541 (6:33194538 G>C,T), RS1000612226 (6:33194223 A>G), RS1001539000 (6:33195886 A>G), RS1001951266 (6:33201835 C>G), RS1002841616 (6:33200610 T>C), RS1002954205 (6:33200336 C>T), RS1003135587 (6:33194110 C>T), RS1003618541 (6:33193816 A>T), RS1004364381 (6:33197627 C>G,T), RS1004436689 (6:33197399 G>C,T), RS1004639676 (6:33195088 G>A), RS1005322811 (6:33201152 G>A,T), RS1005603478 (6:33201445 C>G), RS1005687293 (6:33193889 G>GGA), RS1006477418 (6:33200563 C>A,T)

Disease associations

OMIM: gene MIM:180246 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002160_5	Wegener’s granulomatosis	2.000000e-50

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL1870 (SINGLE PROTEIN), CHEMBL2363070 (PROTEIN FAMILY), CHEMBL2363071 (PROTEIN FAMILY)

Molecules with ChEMBL bioactivity

6 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 326,531 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1023	BEXAROTENE	4	40,951
CHEMBL1071	OXAPROZIN	4	51,044
CHEMBL38	TRETINOIN	4	194,008
CHEMBL705	ALITRETINOIN	4	39,246
CHEMBL295416	PIRINIXIC ACID	2	830
CHEMBL75133	IRX-4204	2	452

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: nhr — 2B. Retinoid X receptors

Most potent curated ligand interactions (7 total), top 7:

Ligand	Action	Affinity	Parameter
LG100268	Agonist	8.5	pIC50
AGN194204	Agonist	8.44	pIC50
alitretinoin	Agonist	8.2	pIC50
LG100754	Antagonist	8.0	pIC50
bexarotene	Agonist	7.7	pIC50
[3H]9-cis-retinoic acid	Full agonist	7.7	pKd
compound 28 [Heitel et al., 2019]	Agonist	6.51	pEC50

ChEMBL bioactivities

382 potent at pChembl≥5 of 442 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.89	EC50	0.13	nM	CHEMBL2325917
9.85	EC50	0.14	nM	CHEMBL2321917
9.30	Ki	0.5	nM	TRETINOIN
9.15	EC50	0.7	nM	CHEMBL5404648
9.10	EC50	0.8	nM	IRX-4204
8.85	EC50	1.4	nM	CHEMBL5404648
8.70	Ki	2	nM	CHEMBL111589
8.70	EC50	2	nM	CHEMBL69091
8.62	Ki	2.4	nM	CHEMBL337393
8.60	Kd	2.5	nM	CHEMBL69091
8.59	EC50	2.6	nM	ALITRETINOIN
8.59	EC50	2.6	nM	CHEMBL5404648
8.52	EC50	3	nM	CHEMBL328481
8.44	Kd	3.6	nM	IRX-4204
8.42	Ki	3.8	nM	ALITRETINOIN
8.41	Ki	3.9	nM	CHEMBL133915
8.41	Ki	3.9	nM	CHEMBL130374
8.40	Ki	4	nM	CHEMBL92284
8.40	Ki	4	nM	CHEMBL42314
8.40	Ki	4	nM	CHEMBL41422
8.35	EC50	4.5	nM	TRETINOIN
8.30	Ki	5	nM	CHEMBL162334
8.28	Ki	5.2	nM	CHEMBL130231
8.23	Ki	5.9	nM	BEXAROTENE
8.22	Ki	6	nM	CHEMBL348797
8.22	EC50	6	nM	ALITRETINOIN
8.15	Ki	7	nM	CHEMBL93518
8.13	Ki	7.4	nM	CHEMBL130232
8.13	Ki	7.4	nM	ALITRETINOIN
8.12	Ki	7.5	nM	CHEMBL288436
8.10	Ki	8	nM	CHEMBL423465
8.10	EC50	7.9	nM	CHEMBL4547228
8.10	EC50	8	nM	CHEMBL111589
8.09	Ki	8.2	nM	CHEMBL424269
8.07	Ki	8.5	nM	CHEMBL133896
8.05	EC50	9	nM	CHEMBL109847
8.05	Ki	9	nM	ALITRETINOIN
8.05	Ki	9	nM	CHEMBL109581
8.00	EC50	10	nM	CHEMBL423465
8.00	Ki	9.9	nM	CHEMBL131122
8.00	Ki	10	nM	CHEMBL41260
8.00	Ki	10	nM	CHEMBL41146
7.99	Ki	10.2	nM	CHEMBL89241
7.96	Ki	11	nM	CHEMBL41890
7.96	Kd	11	nM	ALITRETINOIN
7.94	Ki	11.5	nM	CHEMBL111217
7.92	EC50	12	nM	CHEMBL166201
7.92	Ki	12	nM	CHEMBL208316
7.92	Ki	12	nM	CHEMBL109847
7.92	Ki	12	nM	CHEMBL2372524

PubChem BioAssay actives

334 with measured affinity, of 1003 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-[methyl-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)amino]benzoic acid	726704: Agonist activity at RXR (unknown origin) in presence of RAR agonist Am80	ec50	0.0001	uM
4-[(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)-propylamino]benzoic acid	726704: Agonist activity at RXR (unknown origin) in presence of RAR agonist Am80	ec50	0.0001	uM
tretinoin	41913: Binding affinity for retinoic acid receptor RAR beta	ki	0.0005	uM
trans-(1R,2R)-2-[5-[3,5-bis(trifluoromethyl)phenyl]-4-phenyl-1,3-oxazol-2-yl]cyclopropane-1-carboxylic acid	2024929: Agonist activity at full length human RXR beta expressed in HEK293T cells measured after 16 hrs by Dual-glo luciferase assay	ec50	0.0007	uM
(2E,4E)-3-methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]penta-2,4-dienoic acid	167592: Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR beta	ec50	0.0008	uM
(2E,4E,6Z)-7-(3-methoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-3-methylocta-2,4,6-trienoic acid	199784: Inhibition of [3H]-Targretin binding to Retinoid X receptor RXR beta	ki	0.0020	uM
(2E,4E,6Z)-7-[2-(2,2-difluoroethoxy)-5-(3,5-difluorophenyl)-3-propan-2-ylphenyl]-3-methylocta-2,4,6-trienoic acid	199652: Displacement of [3H]9-cis-RA from RXR beta receptor in CV-1 cells	ki	0.0024	uM
(2E,4E)-3-methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]penta-2,4-dienoic acid	167593: Inhibition of [3H]9-cis-retinoic acid binding to baculovirus expressed retinoic acid receptor RXR-beta	kd	0.0025	uM
alitretinoin	199801: Effective concentrations against Retinoic acid receptor RXR-beta	ec50	0.0026	uM
(2E,4E,6Z)-7-[2-(2,2-difluoroethoxy)-3-propan-2-yl-5-thiophen-2-ylphenyl]-3-methylocta-2,4,6-trienoic acid	199652: Displacement of [3H]9-cis-RA from RXR beta receptor in CV-1 cells	ki	0.0039	uM
(2E,4E,6Z)-7-[2-(2,2-difluoroethoxy)-5-(4-fluorophenyl)-3-propan-2-ylphenyl]-3-methylocta-2,4,6-trienoic acid	199652: Displacement of [3H]9-cis-RA from RXR beta receptor in CV-1 cells	ki	0.0039	uM
(Z)-3-[7-[2-(2,2-difluoroethoxy)-3,5-di(propan-2-yl)phenyl]-1-benzofuran-2-yl]-2-fluorobut-2-enoic acid	199814: Displacement of [3H]9-cis-RA from Retinoic X receptor beta	ki	0.0040	uM
(2E,4E,6Z)-7-[3,5-ditert-butyl-2-(2,2-difluoroethoxy)phenyl]-3-methylocta-2,4,6-trienoic acid	199652: Displacement of [3H]9-cis-RA from RXR beta receptor in CV-1 cells	ki	0.0040	uM
4-[(E)-N-hydroxy-C-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)carbonimidoyl]benzoic acid	199806: Binding affinity towards recombinantly expressed Retinoic acid receptor RXR-beta in baculoviral system, by using 5 nM [3H]targretin in a competitive binding assay	ki	0.0050	uM
(2E,4E,6E)-7-[2-(2,2-difluoroethoxy)-3,5-bis(2-methylbutan-2-yl)phenyl]-6-fluoro-3-methylocta-2,4,6-trienoic acid	199652: Displacement of [3H]9-cis-RA from RXR beta receptor in CV-1 cells	ki	0.0052	uM
Bexarotene	199232: Selective activity towards retinoid X receptor-beta	ki	0.0059	uM
4-[(E)-C-(3-bromo-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-N-hydroxycarbonimidoyl]benzoic acid	199806: Binding affinity towards recombinantly expressed Retinoic acid receptor RXR-beta in baculoviral system, by using 5 nM [3H]targretin in a competitive binding assay	ki	0.0060	uM
(2E,4E,6Z)-7-[2-(2,2-difluoroethoxy)-5-(3-fluorophenyl)-3-propan-2-ylphenyl]-3-methylocta-2,4,6-trienoic acid	199652: Displacement of [3H]9-cis-RA from RXR beta receptor in CV-1 cells	ki	0.0074	uM
6-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid	199814: Displacement of [3H]9-cis-RA from Retinoic X receptor beta	ki	0.0075	uM
4-[ethyl-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)amino]benzoic acid	1630288: Agonist activity at human RXR binding domain and activation domain expressed in human HCT116 cells assessed as rexinoid activity incubated for 24 hrs by luciferase reporter gene based mammalian two-hybrid assay	ec50	0.0079	uM
4-[(E)-N-methoxy-C-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)carbonimidoyl]benzoic acid	199806: Binding affinity towards recombinantly expressed Retinoic acid receptor RXR-beta in baculoviral system, by using 5 nM [3H]targretin in a competitive binding assay	ki	0.0080	uM
(2E,4E,6Z)-7-[2-butoxy-5-(1,1,2,2,2-pentafluoroethyl)-3-propan-2-ylphenyl]-3-methylocta-2,4,6-trienoic acid	199652: Displacement of [3H]9-cis-RA from RXR beta receptor in CV-1 cells	ki	0.0082	uM
(2E,4E,6Z)-7-[2-ethoxy-5-(1,1,2,2,2-pentafluoroethyl)-3-propan-2-ylphenyl]-3-methylocta-2,4,6-trienoic acid	199652: Displacement of [3H]9-cis-RA from RXR beta receptor in CV-1 cells	ki	0.0085	uM
(2E,4E,6Z)-7-(3-ethoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-3-methylocta-2,4,6-trienoic acid	199782: Transcriptional activation of Retinoid X receptor RXR beta	ec50	0.0090	uM
(2E,4E,6Z)-3-methyl-7-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)octa-2,4,6-trienoic acid	199784: Inhibition of [3H]-Targretin binding to Retinoid X receptor RXR beta	ki	0.0090	uM
(2E,4E,6Z)-3-methyl-7-[3-(1,1,2,2,2-pentafluoroethyl)-5-propan-2-yl-2-propoxyphenyl]octa-2,4,6-trienoic acid	199652: Displacement of [3H]9-cis-RA from RXR beta receptor in CV-1 cells	ki	0.0099	uM
(E)-3-[4-[3,5-ditert-butyl-2-(3-fluoropropoxy)phenyl]-1-benzothiophen-2-yl]but-2-enoic acid	199814: Displacement of [3H]9-cis-RA from Retinoic X receptor beta	ki	0.0100	uM
(E)-3-[4-[3,5-ditert-butyl-2-(2,2,2-trifluoroethoxy)phenyl]-1-benzothiophen-2-yl]but-2-enoic acid	199814: Displacement of [3H]9-cis-RA from Retinoic X receptor beta	ki	0.0100	uM
(2E,4E,6E)-7-(3,5-ditert-butylphenyl)-3-methylocta-2,4,6-trienoic acid	199807: Inhibition of [3H]9-cis-RA binding to Retinoid X receptor RXR beta	ki	0.0102	uM
(E)-3-[4-[2-ethoxy-3,5-di(propan-2-yl)phenyl]-1-benzothiophen-2-yl]but-2-enoic acid	199814: Displacement of [3H]9-cis-RA from Retinoic X receptor beta	ki	0.0110	uM
(2E,4E,6E)-7-[3,5-ditert-butyl-2-(2,2-difluoroethoxy)phenyl]-6-fluoro-3-methylocta-2,4,6-trienoic acid	199652: Displacement of [3H]9-cis-RA from RXR beta receptor in CV-1 cells	ki	0.0115	uM
(E)-3-[4-[3,5-ditert-butyl-2-(3,3-difluoropropoxy)phenyl]-1-benzothiophen-2-yl]but-2-enoic acid	199814: Displacement of [3H]9-cis-RA from Retinoic X receptor beta	ki	0.0120	uM
4-[(E)-N-ethoxy-C-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)carbonimidoyl]benzoic acid	199802: Transcriptional activity was evaluated in CV-1 cells transfected with expression vector for Retinoic acid receptor RXR-beta	ec50	0.0120	uM
(2E,4E)-6-[(6-tert-butyl-1,1-dimethyl-2,3-dihydroinden-4-yl)-propylamino]-3-methylhexa-2,4-dienoic acid	263923: Binding affinity to RXRbeta	ki	0.0120	uM
(E)-3-[4-(3,5-ditert-butyl-2-heptoxyphenyl)-1-benzothiophen-2-yl]but-2-enoic acid	199814: Displacement of [3H]9-cis-RA from Retinoic X receptor beta	ki	0.0120	uM
[[(2S)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]phosphonic acid	199814: Displacement of [3H]9-cis-RA from Retinoic X receptor beta	ki	0.0120	uM
(2E,4E,6Z)-7-[2-(2,2-difluoroethoxy)-3-phenyl-5-propan-2-ylphenyl]-3-methylocta-2,4,6-trienoic acid	199652: Displacement of [3H]9-cis-RA from RXR beta receptor in CV-1 cells	ki	0.0123	uM
6-[ethyl-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)amino]pyridine-3-carboxylic acid	1630288: Agonist activity at human RXR binding domain and activation domain expressed in human HCT116 cells assessed as rexinoid activity incubated for 24 hrs by luciferase reporter gene based mammalian two-hybrid assay	ec50	0.0138	uM
6-[ethyl-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)amino]pyridine-3-carboxylic acid	1630288: Agonist activity at human RXR binding domain and activation domain expressed in human HCT116 cells assessed as rexinoid activity incubated for 24 hrs by luciferase reporter gene based mammalian two-hybrid assay	ec50	0.0138	uM
4-[(E)-N-(cyanomethoxy)-C-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)carbonimidoyl]benzoic acid	199806: Binding affinity towards recombinantly expressed Retinoic acid receptor RXR-beta in baculoviral system, by using 5 nM [3H]targretin in a competitive binding assay	ki	0.0140	uM
4-[(E)-C-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)-N-prop-2-enoxycarbonimidoyl]benzoic acid	199806: Binding affinity towards recombinantly expressed Retinoic acid receptor RXR-beta in baculoviral system, by using 5 nM [3H]targretin in a competitive binding assay	ki	0.0150	uM
(E)-3-[4-[3,5-di(propan-2-yl)-2-propoxyphenyl]-1-benzothiophen-2-yl]but-2-enoic acid	199814: Displacement of [3H]9-cis-RA from Retinoic X receptor beta	ki	0.0150	uM
(2E,4E)-3-methyl-5-[2-[(E)-2-(2,6,6-trimethylcyclohexen-1-yl)ethenyl]furan-3-yl]penta-2,4-dienoic acid	199805: Inhibition of [3H]-9-cis RA binding to Retinoid X receptor RXR beta	kd	0.0150	uM
(2E,4E,6E)-7-[3,5-ditert-butyl-2-(2,2,2-trifluoroethoxy)phenyl]-6-fluoro-3-methylocta-2,4,6-trienoic acid	199652: Displacement of [3H]9-cis-RA from RXR beta receptor in CV-1 cells	ki	0.0155	uM
(2E,4E,6Z)-7-[2-(2,2-difluoroethoxy)-5-(2-fluorophenyl)-3-propan-2-ylphenyl]-3-methylocta-2,4,6-trienoic acid	199652: Displacement of [3H]9-cis-RA from RXR beta receptor in CV-1 cells	ki	0.0160	uM
trans-(1S,2S)-2-[5-[3,5-bis(trifluoromethyl)phenyl]-4-phenyl-1,3-oxazol-2-yl]cyclopropane-1-carboxylic acid	2024929: Agonist activity at full length human RXR beta expressed in HEK293T cells measured after 16 hrs by Dual-glo luciferase assay	ec50	0.0160	uM
(E)-3-[5-[3,5-bis(trifluoromethyl)phenyl]-4-phenyl-1,3-oxazol-2-yl]-2-methylprop-2-enoic acid	2024929: Agonist activity at full length human RXR beta expressed in HEK293T cells measured after 16 hrs by Dual-glo luciferase assay	ec50	0.0170	uM
(2E,4E,6Z)-3-methyl-7-[5-(1,1,2,2,2-pentafluoroethyl)-3-propan-2-yl-2-propoxyphenyl]octa-2,4,6-trienoic acid	199652: Displacement of [3H]9-cis-RA from RXR beta receptor in CV-1 cells	ki	0.0172	uM
3-[4-chloro-6-(4,4-dimethyl-2,3-dihydroquinolin-1-yl)pyrimidin-2-yl]oxypropanoic acid	2099261: Partial agonist activity at recombinant human RXR beta LBD (298 to 533 residues) expressed in Escherichia coli Rosetta incubated for 16 hrs by Gal4-hybrid reporter gene based Dual-glo luciferase assay	ec50	0.0180	uM
2-[ethyl-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)amino]pyrimidine-5-carboxylic acid	1630288: Agonist activity at human RXR binding domain and activation domain expressed in human HCT116 cells assessed as rexinoid activity incubated for 24 hrs by luciferase reporter gene based mammalian two-hybrid assay	ec50	0.0182	uM

CTD chemical–gene interactions

78 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Alitretinoin	decreases reaction, increases activity, affects activity, affects cotreatment, increases reaction (+2 more)	7
Tretinoin	increases expression, increases activity, affects binding, affects cotreatment	6
bisphenol A	increases expression, affects binding, decreases reaction, increases activity, affects cotreatment	5
Decitabine	increases expression, decreases expression, decreases reaction	2
Valproic Acid	affects expression, decreases expression	2
2-hydroxyphytanic acid	affects binding	1
testosterone enanthate	affects expression	1
2,4-dichlorophenol	increases activity	1
triphenyl phosphate	affects expression	1
diethyl phthalate	affects binding	1
triphenyltin hydroxide	affects activity, affects binding	1
diisononyl phthalate	affects binding	1
mono-(2-ethylhexyl)phthalate	affects binding	1
butyraldehyde	decreases expression	1
dinonylphthalate	affects binding	1
2,4,6-trichlorophenol	affects binding, decreases reaction, increases activity	1
dimethyl phthalate	affects binding	1
manganese chloride	decreases expression, increases abundance	1
di-n-hexyl phthalate	affects binding	1
butylbenzyl phthalate	affects binding	1
4-hydroxy-2-nonenal	decreases expression	1
didecyl phthalate	affects binding	1
nickel sulfate	increases expression	1
phthalic acid	affects binding	1
di-n-pentyl phthalate	affects binding	1
2-tert-butylphenol	increases activity	1
tetrachlorodian	affects binding, decreases reaction, increases activity	1
diisodecyl phthalate	affects binding	1
3,4-dichlorophenol	increases activity	1
pentanal	decreases expression	1

ChEMBL screening assays

211 unique, capped per target: 183 binding, 28 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1021934	Binding	Activity at Gal4-tagged human RXRbeta receptor expressed in human HeLa cells assessed as relative transcriptional activity by luciferase reporter assay relative to CD3254	Modulating retinoid X receptor with a series of (E)-3-[4-hydroxy-3-(3-alkoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl]acrylic acids and their 4-alkoxy isomers. — J Med Chem
CHEMBL1021935	Functional	Antagonist activity at Gal4-tagged human RXRbeta receptor expressed in human HeLa cells assessed as inhibition of CD3254-induced transcription at >=10 uM by luciferase reporter assay	Modulating retinoid X receptor with a series of (E)-3-[4-hydroxy-3-(3-alkoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl]acrylic acids and their 4-alkoxy isomers. — J Med Chem

Cellosaurus cell lines

9 cell lines: 5 cancer cell line, 3 embryonic stem cell, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A5Z7	SEES3-1V human RXRB, clone1	Embryonic stem cell	Male
CVCL_A5Z8	SEES3-1V human RXRB, clone2	Embryonic stem cell	Male
CVCL_A5Z9	SEES3-1V human RXRB, clone3	Embryonic stem cell	Male
CVCL_D1QF	Abcam K-562 RXRB KO	Cancer cell line	Female
CVCL_D2M1	Abcam Raji RXRB KO	Cancer cell line	Male
CVCL_LF54	GeneBLAzer RXRbeta-UAS-bla HEK 293T	Transformed cell line	Female
CVCL_TJ89	HAP1 RXRB (-) 1	Cancer cell line	Male
CVCL_TJ90	HAP1 RXRB (-) 2	Cancer cell line	Male
CVCL_WQ49	Abcam Jurkat RXRB KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.